Literature DB >> 21328634

Patient views and experiences of making adverse drug reaction reports to the Yellow Card Scheme in the UK.

David J McLernon1, Christine M Bond, Amanda J Lee, Margaret C Watson, Philip C Hannaford, Heather Fortnum, Janet Krska, Claire Anderson, Elizabeth Murphy, Anthony Avery.   

Abstract

PURPOSE: To describe the characteristics of patient reporters to the UK's Yellow Card Scheme (YCS) and the suspect drugs reported, and to determine patient views and experiences of making a Yellow Card report.
METHODS: A questionnaire was developed for distribution by the Medicines and Healthcare products Regulatory Agency (MHRA) to all patients reporting through the YCS between March 2008 and January 2009. Associations between reporting method (online, postal and telephone) and questionnaire responses were examined using Pearson's Chi-squared test.
RESULTS: Evaluable questionnaires were returned by 1362 out of 2008 reporters (68%). Respondents' median (IQR) age was 56.5 (43.0, 67.0) years, 910 (66.8%) were female, 1274 (93.5%) were white and 923 (67.8%) had at least a further education qualification. The most frequent reporting method was postal (59.8%), followed by online (32.8%) and telephone (6.3%). Online reporters were younger with a higher education level than those using other reporting methods. Most respondents, 1274 (93.6%), thought that the report was fairly or very easy to complete, although many identified the need for improvements to the system. One third (n = 448; 32.9%) expected feedback from the MHRA and 828 (60.8%) would have liked feedback. Almost all respondents (n = 1302; 95.6%) would report again.
CONCLUSIONS: The majority of patients found the current methods of reporting suspected ADRs easy to use and would recommend them to others. Different methods of reporting were used by different demographic subgroups of reporters. Improvements to the system, including the provision of feedback to reporters, could be made.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21328634     DOI: 10.1002/pds.2117

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  16 in total

Review 1.  Experiences with adverse drug reaction reporting by patients: an 11-country survey.

Authors:  Florence van Hunsel; Linda Härmark; Shanthi Pal; Sten Olsson; Kees van Grootheest
Journal:  Drug Saf       Date:  2012-01-01       Impact factor: 5.606

2.  How patient reporters identify adverse drug reactions: a qualitative study of reporting via the UK Yellow Card Scheme.

Authors:  Janet Krska; Claire Anderson; Elizabeth Murphy; Anthony J Avery
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

3.  The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective.

Authors:  Claire Anderson; Janet Krska; Elizabeth Murphy; Anthony Avery
Journal:  Br J Clin Pharmacol       Date:  2011-11       Impact factor: 4.335

4.  Are consumers ready to take part in the Pharmacovigilance System?--a Portuguese preliminary study concerning ADR reporting.

Authors:  Cristiano Matos; Florence van Hunsel; João Joaquim
Journal:  Eur J Clin Pharmacol       Date:  2015-05-26       Impact factor: 2.953

5.  Adverse Drug Reaction Reporting Practices Among United Arab Emirates Pharmacists and Prescribers.

Authors:  Amira S A Said; Nadia Hussain
Journal:  Hosp Pharm       Date:  2017-05-01

6.  Patient Reporting of Adverse Drug Reactions: An International Survey of National Competent Authorities' Views and Needs.

Authors:  Cristiano Matos; Linda Härmark; Florence van Hunsel
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

7.  Public confidence in ADR identification and their views on ADRreporting: mixed methods study.

Authors:  Narumol Jarernsiripornkul; Arunrot Patsuree; Janet Krska
Journal:  Eur J Clin Pharmacol       Date:  2016-11-11       Impact factor: 2.953

Review 8.  A plea for a more epidemiological and patient-oriented pharmacovigilance.

Authors:  Veronica Scurti; Marilena Romero; Gianni Tognoni
Journal:  Eur J Clin Pharmacol       Date:  2011-07-20       Impact factor: 2.953

9.  The Role of European Patient Organizations in Pharmacovigilance.

Authors:  Cristiano Matos; Gerda Weits; Florence van Hunsel
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

10.  Effect of pharmacist involvement on patient reporting of adverse drug reactions: first Italian study.

Authors:  Roberto Leone; Ugo Moretti; Paola D'Incau; Anita Conforti; Lara Magro; Riccardo Lora; Giampaolo Velo
Journal:  Drug Saf       Date:  2013-04       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.